Glatiramer acetate during early pregnancy: A prospective cohort study
Abstract
Background:
Only limited data are available on whether glatiramer acetate exposure during pregnancy has an effect on perinatal outcome.
Objective:
To determine the effect of glatiramer acetate exposure during pregnancy on pregnancy outcomes in women with multiple sclerosis.
Methods:
We compared the outcome of pregnancies of women with multiple sclerosis exposed to glatiramer acetate with pregnancies unexposed to disease-modifying therapies. Women were enrolled into the German Multiple Sclerosis and Pregnancy registry. A standardized questionnaire was administered during pregnancy and postpartum. Detailed information on course of multiple sclerosis and pregnancy, concomitant medications, labor, delivery, and outcome of pregnancy was obtained.
Results:
We collected data on 246 multiple sclerosis pregnancies, 151 exposed to glatiramer acetate and 95 unexposed to disease-modifying therapies during pregnancy. Three (2.2%) congenital anomalies occurred in the exposed and 6 (6.7%) in the control group. We did not observe an increase in other adverse pregnancy or delivery outcomes including spontaneous abortions, preterm birth, Cesarean sections, or reduced birth weight in the exposed group.
Conclusion:
Our data provide further evidence that glatiramer acetate exposure during the first trimester of pregnancy appears safe and without teratogenic effect. These findings provide important additive knowledge to better counsel women with multiple sclerosis in planning a pregnancy.
Get full access to this article
View all access and purchase options for this article.
References
1. Orton SM, Herrera BM, Yee IM, et al. Sex ratio of multiple sclerosis in Canada: A longitudinal study. Lancet Neurol 2006; 5(11): 932–936.
2. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67(7): 1242–1249.
3. Kinkel RP, Kollman C, O’Connor P, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006; 66(5): 678–684.
4. Comi G, Martinelli V, Rodegher M, et al. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler 2013; 19(8): 1074–1083.
5. Lu E, Wang BW, Guimond C, et al. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology 2012; 79(11): 1130–1135.
6. Lu E, Dahlgren L, Sadovnick A, et al. Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs. Mult Scler 2012; 18(4): 460–467.
7. Giannini M, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: A prospective observational multicentric study. BMC Neurol 2012; 12: 124.
8. Hellwig K, Haghikia A, Rockhoff M, et al. Multiple sclerosis and pregnancy: Experience from a nationwide database in Germany. Ther Adv Neurol Disord 2012; 5(5): 247–253.
9. Fragoso YD, Adoni T, Alves-Leon SV, et al. Long-term effects of exposure to disease-modifying drugs in the offspring of mothers with multiple sclerosis: A retrospective chart review. CNS Drugs 2013; 27(11): 955–961.
10. Hellwig K, Beste C, Schimrigk S, et al. Immunomodulation and postpartum relapses in patients with multiple sclerosis. Ther Adv Neurol Disord 2009; 2(1): 7–11.
11. Fragoso YD, Finkelsztejn A, Comini-Frota ER, et al. Pregnancy and multiple sclerosis: the initial results from a Brazilian database. Arq Neuropsiquiatr 2009; 67(3A): 657–660.
12. Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult Scler 2009; 15(9): 1037–1042.
13. Coyle PK, Johnson K, Pardo L, et al. Pregnancy outcomes in patients with multiple sclerosis treated with glatiramer acetate (Copaxone). Neurology 2003; 60: A60.
14. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria.” Ann Neurol 2005; 58(6): 840–846.
15. Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: Results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler 2011; 17(8): 958–963.
16. Bove R, Alwan S, Friedman JM, et al. Management of multiple sclerosis during pregnancy and the reproductive years: A systematic review. Obstet Gynecol 2014; 124(6): 1157–1168.
17. Queisser-Luft A, Spranger J. Congenital malformations. Dtsch Arztebl Int 2006; 103(38): A–2464, http://www.aerzteblatt.de/int/article.asp?id=58026
18. European Surveillance of Congenital Anomalies (eurocat). Detailed congenital anomaly coding guidelines guide 1.4, Section 3.5, 2013, http://www.eurocat-network.eu/aboutus/datacollection/guidelinesforregistration/guide1_4
19. US Department of Health and Human Services Food and Drug Administration. Guidance for industry: Establishing pregnancy exposure registries, 2002, http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071639.pdf
20. World Health Organization (WHO). Neonatal and perinatal mortality: Country, regional and global estimates (WHO Library Cataloguing-in-Publication Data). Geneva: WHO, 2006.
21. World Health Organization (WHO). ICD-10: International statistical classification of diseases and related health problems, 10th revision, vol. 2, 2nd ed. Geneva: WHO, 2004.
22. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res 2011; 46(3): 399–424.
23. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69(2): 292–302.
24. Fernandez Liguori N, Klajn D, Acion L, et al. Epidemiological characteristics of pregnancy, delivery, and birth outcome in women with multiple sclerosis in Argentina (EMEMAR study). Mult Scler 2009; 15(5): 555–562.
25. Fragoso YD, Finkelsztejn A, Kaimen-Maciel DR, et al. Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: A retrospective, multicentre case series. CNS Drugs 2010; 24(11): 969–976.
26. Finkelsztejn A, Fragoso YD, Ferreira MLB, et al. The Brazilian database on pregnancy in multiple sclerosis. Clin Neurol Neurosur 2011; 113(4): 277–280.
27. Hellwig K, Haghikia A, Gold R. Parenthood and immunomodulation in patients with multiple sclerosis. J Neurol 2010; 257(4): 580–583.
28. Salminen HJ, Leggett H, Boggild M. Glatiramer acetate exposure in pregnancy: Preliminary safety and birth outcomes. J Neurol 2010; 257(12): 2020–2023.
29. Neuhaus O, Kieseier BC, Hartung HP. Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis. J Neurol Sci 2007; 259(1–2): 27–37.
30. Infante-Rivard C, Jacques L. Empirical study of parental recall bias. Am J Epidemiol 2000; 152(5): 480–486.
31. Daniel S, Koren G, Lunenfeld E, et al. Immortal time bias in drug safety cohort studies: Spontaneous abortion following nonsteroidal antiinflammatory drug exposure. Am J Obstet Gynecol 2015; 212: 307.e1–307.e16.
Cite article
Cite article
Cite article
OR
Download to reference manager
If you have citation software installed, you can download article citation data to the citation manager of your choice
Information, rights and permissions
Information
Published In
Article first published online: January 11, 2016
Issue published: May 2016
Keywords
History
Manuscript received: August 31, 2015
Revision received: November 25, 2015
Manuscript accepted: November 29, 2015
Published online: January 11, 2016
Issue published: May 2016
PubMed: 26754804
Authors
Metrics and citations
Metrics
Article usage*
Total views and downloads: 846
*Article usage tracking started in December 2016
Altmetric
See the impact this article is making through the number of times it’s been read, and the Altmetric Score.
Learn more about the Altmetric Scores
Articles citing this one
Web of Science: 58 view articles Opens in new tab
Crossref: 65
- Multiple sclerosis, disease-modifying drugs and risk for adverse perin...
- Neuroimmunological Disorders
- Safety evaluations of offspring breastfed by mothers receiving glatira...
- Pregnancy and multiple sclerosis: 2022 recommendations from the French...
- Pregnancy outcomes after early fetal exposure to injectable first‐line...
- Maternal Multiple Sclerosis and Health Outcomes Among the Children: A ...
- Preventive Approaches in Women's Neurology: Prepartum, Pregnancy, and ...
- Eighteen-month safety analysis of offspring breastfed by mothers recei...
- Disease modifying therapy switching in relapsing multiple sclerosis: A...
- Treatment Challenges in Multiple Sclerosis – A Continued Role for Glat...
- Pregnancy, Fetal, and Infant Outcomes Following Maternal Exposure to G...
- Literatur
- Updated Perspectives on the Challenges of Managing Multiple Sclerosis ...
- Disease Reactivation after Fingolimod Discontinuation in Pregnant Mult...
- Treatment of Women with Multiple Sclerosis Planning Pregnancy
- Pregnancy with multiple sclerosis
- Family Planning for People with Multiple Sclerosis in Saudi Arabia: an...
- The German Multiple Sclerosis and Pregnancy Registry: rationale, objec...
- Switching treatments in clinically stable relapsing remitting multiple...
- Disease-Modifying Drugs and Family Planning in People with Multiple Sc...
- The Development of Cladribine Tablets for the Treatment of Multiple Sc...
- Discontinuation of disease-modifying treatments in multiple sclerosis ...
- Effect of assisted reproductive technology on multiple sclerosis relap...
- A systematic review and meta-analyses of pregnancy and fetal outcomes ...
- Pharmacotherapeutic considerations in women with multiple sclerosis
- Teriflunomide vs injectable disease modifying therapies for relapsing ...
- Safety of potential breast milk exposure to IFN-β or glatiramer acetat...
- Sex effects across the lifespan in women with multiple sclerosis
- Neuroimmunologic disorders in pregnancy
- Pregnancy-related issues in women with multiple sclerosis: an evidence...
- Use of glatiramer acetate between 2010–2015: effectiveness, safety and...
- Pregnancy and multiple sclerosis: Risk of unplanned pregnancy and drug...
- Relapses and obstetric outcomes in women with multiple sclerosis plann...
- Multiple sclerosis and pregnancy
- Women’s Health: Contemporary Management of MS in Pregnancy and Post-Pa...
- Reaching an evidence-based prognosis for personalized treatment of mul...
- We need to conduct clinical trials of disease-modifying therapy in pre...
- Management of Demyelinating Disorders in Pregnancy
- Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple ...
- Risks and risk management in modern multiple sclerosis immunotherapeut...
- Demyelinating Disease and Pregnancy
- Drugs for Soft Tissue Autoimmune Disorders
- Intravenous immunoglobulin treatment in multiple sclerosis: A prospect...
- Patient awareness about family planning represents a major knowledge g...
- Evaluation of reproductive health in female patients with multiple scl...
- First-line therapy in relapsing remitting multiple sclerosis
- Survey of diagnostic and treatment practices for multiple sclerosis (M...
- Rituximab before and during pregnancy
- ECTRIMS/EAN Guideline on the pharmacological treatment of people with ...
- An Update on the Use of Disease-Modifying Therapy in Pregnant Patients...
- ECTRIMS / EAN guideline on t...
- Evaluation of pregnancy outcomes in patients with multiple sclerosis a...
- Risikomanagement und alltagspraktische Aspekte
- Pregnancy Outcomes from the Branded Glatiramer Acetate Pregnancy Datab...
- Treatment of multiple sclerosis during pregnancy – safety consideratio...
- Welcher MS-Patient braucht was?
- Drugs That Act on the Immune System: Immunosuppressive and Immunostimu...
- Identification and Prioritization of Important Attributes of Disease-M...
- Considerations on long-term immuno-intervention in the treatment of mu...
- Interferon-beta exposure during first trimester is safe in women with ...
- Multiple sclerosis disease-modifying therapy and pregnancy
- Pregnancy and the Use of Disease-Modifying Therapies in Patients with ...
- A place of first-line drugs in treatment of multiple sclerosis
- Interdisciplinary Risk Management in the Treatment of Multiple Scleros...
- Familieplanlegging, graviditet og amming ved multippel sklerose
Figures and tables
Figures & Media
Tables
View Options
Get access
Access options
If you have access to journal content via a personal subscription, university, library, employer or society, select from the options below:
loading institutional access options
Alternatively, view purchase options below:
Purchase 24 hour online access to view and download content.
Access journal content via a DeepDyve subscription or find out more about this option.
